Loss of Sh3gl2/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior

Neoplasia (United States)

Volumn 15, Issue 7, 2013, Pages 749-760

  Majumdar, Shyama ^a   Gong, Edward M ^a,h   Di Vizio, Dolores ^a,b   Dreyfuss, Jonathan ^c   DeGraff, David J ^d   Hager, Martin H ^a,i   Park, Peter J ^e   Bellmunt, Joaquim ^f   Matusik, Robert J ^d   Rosenberg, Jonathan E ^g,j   Adam, Rosalyn M ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e Harvard Medical School Center for Biomedical Informatics   (United States)

^f HOSPITAL DEL MAR   (Spain)

^g HARVARD MEDICAL SCHOOL   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ DAIICHI SANKYO CO   (Japan)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ENDOPHILIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; STAT3 PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOINFORMATICS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE SRC; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA; TUMOR GROWTH; TUMOR INVASION;

EID: 84879626134     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121956     Document Type: Article

References (49)

1. Jemal A, Siegel R, Xu J, and Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin 60, 277-300.
2. Riley GF, Potosky AL, Lubitz JD, and Kessler LG (1995). Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 33, 828-841.
3. Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M, Hennenlotter J, Kruck S, and Stenzl A (2009). Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 27, 295-300.
4. Degraff DJ, Cates JM, Mauney JR, Clark PE, Matusik RJ, and Adam RM (2011). When urothelial differentiation pathways go wrong: implications for bladder cancer development and progression. Urol Oncol.
5. Knowles MA, Platt FM, Ross RL, and Hurst CD (2009). Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev 28, 305-316.
6. Hynes NE and MacDonald G (2009). ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21, 177-184.
7. Philips GK, Halabi S, Sanford BL, Bajorin D, and Small EJ (2008). A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. BJU Int 101, 20-25.
8. Philips GK, Halabi S, Sanford BL, Bajorin D, and Small EJ (2009). A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol 20, 1074-1079.
9. Wulfing C, Machiels JP, Richel DJ, Grimm MO, Treiber U, De Groot MR, Beuzeboc P, Parikh R, Petavy F, and El-Hariry IA (2009). A single-arm, multi-center, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 115, 2881-2890.
10. Petrylak DP, Tangen CM, Van Veldhuizen PJ Jr, Goodwin JW, Twardowski PW, Atkins JN, Kakhil SR, Lange MK, Mansukhani M, and Crawford ED (2010). Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int 105, 317-321.
11. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, Zhang J, Soden R, Hayakawa M, Kreiman G, et al. (2004). A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA 101, 6062-6067.
12. Little MH, Brennan J, Georgas K, Davies JA, Davidson DR, Baldock RA, Beverdam A, Bertram JF, Capel B, Chiu HS, et al. (2007). A high-resolution anatomical ontology of the developing murine genitourinary tract. Gene Expr Patterns 7, 680-699.
13. McMahon AP, Aronow BJ, Davidson DR, Davies JA, Gaido KW, Grimmond S, Lessard JL, Little MH, Potter SS, Wilder EL, et al. (2008). GUDMAP: the genitourinary developmental molecular anatomy project. J Am Soc Nephrol 19, 667-671.
14. Smyth GK (2004). Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3, Article3.
15. Smyth GK (2005). Limma: linear models for microarray data. In Bioinformatics and Computational Biology Solutions using R and Bioconductor (1st ed). R Gentleman, V Carey, S Dudoit, R Izarry, and W Huber (Eds). Springer, New York. p. 492.
16. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, et al. (2004). Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5, R80.
17. Benjamini Y and Hochberg Y (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B 57, 289-300.
18. Dyrskjot L, Kruhoffer M, Thykjaer T, Marcussen N, Jensen JL, Moller K, and Orntoft TF (2004). Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 64, 4040-4048.
19. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, and Cordon-Cardo C (2006). Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 24, 778-789.
20. Lee JS, Leem SH, Lee SY, Kim SC, Park ES, Kim SB, Kim SK, Kim YJ, Kim WJ, and Chu IS (2010). Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol 28, 2660-2667.
21. Adam RM, Borer JG, Williams J, Eastham JA, Loughlin KR, and Freeman MR (1999). Amphiregulin is coordinately expressed with heparin-binding epidermal growth factor-like growth factor in the interstitial smooth muscle of the human prostate. Endocrinology 140, 5866-5875.
22. Kim J, Ji M, DiDonato JA, Rackley RR, Kuang M, Sadhukhan PC, Mauney JR, Keay SK, Freeman MR, Liou LS, et al. (2011). An hTERT-immortalized human urothelial cell line that responds to anti-proliferative factor. In Vitro Cell Dev Biol Anim 47, 2-9.
23. Ramachandran A, Ranpura SA, Gong EM, Mulone M, Cannon GM Jr, and Adam RM (2010). An Akt-and Fra-1-dependent pathway mediates platelet-derived growth factor-induced expression of thrombomodulin, a novel regulator of smooth muscle cell migration. Am J Pathol 177, 119-131.
24. Stehr M, Adam RM, Khoury J, Zhuang L, Solomon KR, Peters CA, and Freeman MR (2003). Platelet derived growth factor-BB is a potent mitogen for rat ureteral and human bladder smooth muscle cells: dependence on lipid rafts for cell signaling. J Urol 169, 1165-1170.
25. Oottamasathien S, Wang Y, Williams K, Franco OE, Wills ML, Thomas JC, Saba K, Sharif-Afshar AR, Makari JH, Bhowmick NA, et al. (2007). Directed differentiation of embryonic stem cells into bladder tissue. Dev Biol 304, 556-566.
26. DeGraff DJ, Clark PE, Cates JM, Yamashita H, Robinson VL, Yu X, Smolkin ME, Chang SS, Cookson MS, Herrick MK, et al. (2012). Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. PLoS One 7, e36669.
27. Strand DW, Degraff DJ, Jiang M, Sameni M, Franco OE, Love HD, Hayward W, Lin-Tsai O, Wang A, Cates JM, et al. (2013). Deficiency in metabolic regulators PPARγ and PTEN cooperates to drive keratinizing squamous metaplasia in novel models of human tissue regeneration. Am J Pathol 182, 449-459.
28. Giachino C, Lantelme E, Lanzetti L, Saccone S, Bella Valle G, and Migone N (1997). A novel SH3-containing human gene family preferentially expressed in the central nervous system. Genomics 41, 427-434.
29. Sinha S, Chunder N, Mukherjee N, Alam N, Roy A, Roychoudhury S, and Panda CK (2008). Frequent deletion and methylation in SH3GL2 and CDKN2A loci are associated with early-and late-onset breast carcinoma. Ann Surg Oncol 15, 1070-1080.
30. Ghosh A, Ghosh S, Maiti GP, Sabbir MG, Alam N, Sikdar N, Roy B, Roychoudhury S, and Panda CK (2009). SH3GL2 and CDKN2A/2B loci are independently altered in early dysplastic lesions of head and neck: correlation with HPV infection and tobacco habit. J Pathol 217, 408-419.
31. Osterberg L, Levan K, Partheen K, Delle U, Olsson B, Sundfeldt K, and Horvath G (2009). Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas. BMC Cancer 9, 368.
32. Kong SW, Hwang KB, Kim RD, Zhang BT, Greenberg SA, Kohane IS, and Park PJ (2005). CrossChip: a system supporting comparative analysis of different generations of Affymetrix arrays. Bioinformatics 21, 2116-2117.
33. Dreyfuss JM, Johnson MD, and Park PJ (2009). Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers. Mol Cancer 8, 71.
34. Smeets W, Pauwels R, Laarakkers L, Debruyne F, and Geraedts J (1987). Chromosomal analysis of bladder cancer. III. Nonrandom alterations. Cancer Genet Cytogenet 29, 29-41.
35. Ruppert JM, Tokino K, and Sidransky D (1993). Evidence for two bladder cancer suppressor loci on human chromosome 9. Cancer Res 53, 5093-5095.
36. Cairns P, Shaw ME, and Knowles MA (1993). Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene 8, 1083-1085.
37. Soubeyran P, Kowanetz K, Szymkiewicz I, Langdon WY, and Dikic I (2002). Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors. Nature 416, 183-187.
38. Petrelli A, Gilestro GF, Lanzardo S, Comoglio PM, Migone N, and Giordano S (2002). The endophilin-CIN85-Cbl complex mediates ligand-dependent down-regulation of c-Met. Nature 416, 187-190.
39. Sparks AB, Hoffman NG, McConnell SJ, Fowlkes DM, and Kay BK (1996). Cloning of ligand targets: systematic isolation of SH3 domain-containing proteins. Nat Biotechnol 14, 741-744.
40. Knowles MA (2007). Tumor suppressor loci in bladder cancer. Front Biosci 12, 2233-2251.
41. Pollard C, Smith SC, and Theodorescu D (2010). Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC). Expert Rev Mol Med 12, e10.
42. Keen AJ and Knowles MA (1994). Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder. Oncogene 9, 2083-2088.
43. Farrell WE, Simpson DJ, Bicknell JE, Talbot AJ, Bates AS, and Clayton RN (1997). Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes. Cancer Res 57, 2703-2709.
44. Parris CN, Harris JD, Griffin DK, Cuthbert AP, Silver AJ, and Newbold RF (1999). Functional evidence of novel tumor suppressor genes for cutaneous malignant melanoma. Cancer Res 59, 516-520.
45. Pollock PM, Welch J, and Hayward NK (2001). Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development. Cancer Res 61, 1154-1161.
46. Dasgupta S, Jang JS, Shao C, Mukhopadhyay ND, Sokhi UK, Das SK, Brait M, Talbot C, Yung RC, Begum S, et al. (2012). SH3GL2 is frequently deleted in non-small cell lung cancer and downregulates tumor growth by modulating EGFR signaling. J Mol Med (Berl) 91, 381-393.
47. Chiang GJ, Billmeyer BR, Canes D, Stoffel J, Moinzadeh A, Austin CA, Kosakowski M, Rieger-Christ KM, Libertino JA, and Summerhayes IC (2005). The src-family kinase inhibitor PP2 suppresses the in vitro invasive phenotype of bladder carcinoma cells via modulation of Akt. BJU Int 96, 416-422.
48. Ho PL, Lay EJ, Jian W, Parra D, and Chan KS (2012). Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer. Cancer Res 72, 3135-3142.
49. Green TP, Fennell M, Whittaker R, Curwen J, Jacobs V, Allen J, Logie A, Hargreaves J, Hickinson DM, Wilkinson RW, et al. (2009). Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol 3, 248-261.